Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/33443548/ below:

Incidence of Cervical Cancer in Puerto Rico, 2001-2017

Affiliations

• ¹ Comprehensive Cancer Center, The University of Puerto Rico, San Juan, Puerto Rico.
• ² Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.
• ³ Puerto Rico Central Cancer Registry, Cancer Control and Population Sciences Division, Comprehensive Cancer Center, The University of Puerto Rico, San Juan, Puerto Rico.
• ⁴ Center for Health Services Research, Department of Management, Policy, and Community Health, UTHealth School of Public Health, Houston, Texas.

• PMID: 33443548
• PMCID: PMC7809611
• DOI: 10.1001/jamaoncol.2020.7488

Item in Clipboard

Ana Patricia Ortiz et al. JAMA Oncol. 2021.

• ¹ Comprehensive Cancer Center, The University of Puerto Rico, San Juan, Puerto Rico.
• ² Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.
• ³ Puerto Rico Central Cancer Registry, Cancer Control and Population Sciences Division, Comprehensive Cancer Center, The University of Puerto Rico, San Juan, Puerto Rico.
• ⁴ Center for Health Services Research, Department of Management, Policy, and Community Health, UTHealth School of Public Health, Houston, Texas.

• PMID: 33443548
• PMCID: PMC7809611
• DOI: 10.1001/jamaoncol.2020.7488

Item in Clipboard

This cohort study examines recent trajectories in the incidence of cervical cancer in Puerto Rico by age and among birth cohorts.

PubMed Disclaimer

Conflict of Interest Disclosures: Dr Ortiz reported receiving grants from the National Institutes of Health during the conduct of the study; and personal fees from serving as a consultant for Merck outside the submitted work. Dr Ortiz-Ortiz reported receiving grants from the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries and the National Cancer Institute (NCI) during the conduct of the study; and grants from Abbvie Corp outside the submitted work. Dr Colón-López reported receving personal fees from serving as a consultant for Merck & Co outside the submitted work. Dr Tortolero-Luna reported receiving grants from the NCI and the CDC during the conduct of the study. Mr Torres-Cintrón reported receiving grants from CDC National Program of Cancer Registries during the conduct of the study; and grants from AbbVie Corp outside the submitted work. Dr Deshmukh reported receiving personal fees from Merck Inc outside the submitted work. No other disclosures were reported.

A, Hysterectomy-corrected and hysterectomy-uncorrected cervical cancer incidence rates. B, Uncorrected cervical cancer incidence rates according to age. C, Hysterectomy-corrected cervical cancer incidence rates according to age. Data markers represent observed incidence rates (cases per 100 000 person-years). Rates are age-adjusted to the 2000 US population. Incidence trends were evaluated for 3 age groups: younger than 35 years (ever vaccine age–eligible group and a portion of screening age–eligible group), 35 to 64 years (screening age–eligible group), and 65 years or older (screening age–ineligible group). The annual percentage change (APC) characterizes trend, a single regression line on a log scale fitted over a fixed interval, whereas the mean annual percentage change (MAPC) is a weighted mean of the APCs from the joinpoint model with the weights equal to the length of the APC interval. Given that there was no joinpoint observed for age groups 35 to 64 years and 65 years or older, the MAPC is equivalent to the APC. ^aStatistically significant incidence trend (P < .05).

For comparison, we chose the reference year corresponding to the 1961 cohort (this arbitrary choice of reference year value does not affect result interpretation). Shaded bands indicate 95% CIs. Incidence rate ratios were adjusted for age and calendar period effects. ^aNot reported because there were fewer than 16 cases in the time interval.

• Recent cervical cancer incidence, stage at diagnosis, and mortality trends in Puerto Rico, 2001-2019.

  Ortiz AP, Torres-Cintrón CR, Santiago-Rodríguez EJ, Ramos-Cartagena JM, Suárez-Ramos T, Damgacioglu H, Colón-López V, Ortiz-Ortiz KJ, Deshmukh AA. Ortiz AP, et al. BMC Med. 2024 Aug 13;22(1):327. doi: 10.1186/s12916-024-03535-4. BMC Med. 2024. PMID: 39135060 Free PMC article.

1. 1. Deshmukh AA, Suk R, Shiels MS, et al. . Incidence trends and burden of human papillomavirus–associated cancers among women in the United States, 2001-2017. J Natl Cancer Inst. 2020;djaa128. doi:10.1093/jnci/djaa128 - DOI - PMC - PubMed
2. 1. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351. doi:10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z - DOI - PubMed
3. 1. Rosenberg PS, Check DP, Anderson WF. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2296-2302. doi:10.1158/1055-9965.EPI-14-0300 - DOI - PMC - PubMed
4. 1. Burger EA, Smith MA, Killen J, et al. . Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health. 2020;5(4):e213-e222. doi:10.1016/S2468-2667(20)30006-2 - DOI - PMC - PubMed
5. 1. Centers for Disease Control and Prevention . BRFSS prevalence & trends data. Published 2020. Accessed September 3, 2020. https://www.cdc.gov/brfss/brfssprevalence/

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3